Elshanawane et al., 2014 - Google Patents
Quantitative determination of telmisartan, ramipril, amlodipine besylate, and atorvastatin calcium by HPLCElshanawane et al., 2014
- Document ID
- 17585161885351940026
- Author
- Elshanawane A
- Abdelaziz L
- Kamal M
- Hafez H
- Publication year
- Publication venue
- Journal of Liquid Chromatography & Related Technologies
External Links
Snippet
Telmisartan is angiotensin-II-receptor antagonist (ARA II), which is used in treatment of hypertension alone or in combination with other antihypertensive drugs such as Ramipril and Amlodipine besylate or in combination with antihyperlipidemic agent such as …
- 239000005537 C09CA07 - Telmisartan 0 title abstract description 70
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Elshanawane et al. | Quantitative determination of telmisartan, ramipril, amlodipine besylate, and atorvastatin calcium by HPLC | |
| Jain et al. | Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form | |
| Issa et al. | Simultaneous determination of paracetamol, caffeine, domperidone, ergotamine tartrate, propyphenazone, and drotaverine HCl by high performance liquid chromatography | |
| Varghese et al. | Quantitative simultaneous determination of amlodipine, valsartan, and hydrochlorothiazide in “Exforge HCT” tablets using high-performance liquid chromatography and high-performance thin-layer chromatography | |
| Dange et al. | Optimization and validation of RP-HPLC method for simultaneous estimation of palbociclib and letrozole | |
| Kamble et al. | Validated HPLC and HPTLC method for simultaneous quantitation of amlodipine besylate and olmesartan medoxomil in bulk drug and formulation | |
| El-Gindy et al. | Stability-Indicating HPLC method for simultaneous determination of captopril, indapamide, and their related compounds | |
| Vethe et al. | A method for direct monitoring of atorvastatin adherence in cardiovascular disease prevention: quantification of the total exposure to parent drug and major metabolites using 2-channel chromatography and tandem mass spectrometry | |
| Pandya et al. | Simultaneous densitometric analysis of amlodipine, hydrochlorothiazide, lisinopril, and valsartan by HPTLC in pharmaceutical formulations and human plasma | |
| Arayne et al. | Simultaneous determination of metformin, captopril, lisinopril, and enalapril by RP-HPLC: its applications in dosage formulations and in human serum | |
| Deshmukh et al. | Development and validation of novel HPTLC method for the simultaneous estimation of amlodipine besylate and telmisartan in tablet dosage form using ICH Q2 (R1) directions | |
| Arayne et al. | RP-HPLC method for the quantitative determination of fexofenadine hydrochloride in coated tablets and human serum | |
| Momin et al. | Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation | |
| Shaalan et al. | Gradient HPLC-DAD determination of the antihypertensive mixture of amlodipine besylate, valsartan, and hydrochlorothiazide in combined pharmaceutical tablets | |
| Bodapati et al. | Stability indicating RP-HPLC studies for the estimation of irbesartan and amlodipine besylate in pharmaceutical formulations and identification and characterization of degradants using LC-MS | |
| Kim et al. | No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects | |
| Hafez et al. | Quantitative determination of amlodipine besylate, losartan potassium, valsartan and atorvastatin calcium by HPLC in their pharmaceutical formulations | |
| Özkan | Simultaneous determination of losartan potassium and hydrochlorothiazide from tablets and human serum by RP-HPLC | |
| Joshi et al. | Development and validation of RP-HPLC method for simultaneous estimation of three-component tablet formulation containing acetaminophen, chlorzoxazone, and aceclofenac | |
| Danafar et al. | Method validation of amlodipine and atorvastatin by liquid chromatography–mass spectrometry (LC–MS) method in human plasma | |
| Breier et al. | Validation of UV spectrophotometric method for fexofenadine hydrochloride in pharmaceutical formulations and comparison with HPLC | |
| Casamenti et al. | Development of an HPLC method for the toxicological screening of central nervous system drugs | |
| Salvadori et al. | Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics | |
| Elshanawane et al. | Quantitative determination of four angiotensin-II-receptor antagonists in presence of hydrochlorothiazide by a gradient technique HPLC in their pharmaceutical preparations | |
| Stolarczyk et al. | Chromatographic and densitometric analysis of hydrochlorothiazide, walsartan, kandesartan, and enalapril in selected complex hypotensive drugs |